BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7895165)

  • 1. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides.
    Avva RR; Cresswell P
    Immunity; 1994 Dec; 1(9):763-74. PubMed ID: 7895165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
    Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
    J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules.
    Denzin LK; Hammond C; Cresswell P
    J Exp Med; 1996 Dec; 184(6):2153-65. PubMed ID: 8976171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
    Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
    J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM.
    Weber DA; Evavold BD; Jensen PE
    Science; 1996 Oct; 274(5287):618-20. PubMed ID: 8849454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the HLA-DM interaction site on HLA-DR molecules.
    Doebele RC; Busch R; Scott HM; Pashine A; Mellins ED
    Immunity; 2000 Oct; 13(4):517-27. PubMed ID: 11070170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
    Sherman MA; Weber DA; Jensen PE
    Immunity; 1995 Aug; 3(2):197-205. PubMed ID: 7648393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
    Kropshofer H; Vogt AB; Hämmerling GJ
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
    Denzin LK; Cresswell P
    Cell; 1995 Jul; 82(1):155-65. PubMed ID: 7606781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.
    Vogt AB; Kropshofer H; Moldenhauer G; Hämmerling GJ
    Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9724-9. PubMed ID: 8790398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.
    Demotz S; Danieli C
    Mol Immunol; 1993 Dec; 30(18):1623-32. PubMed ID: 8272076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clip binds to HLA class II using methionine-based, allele-dependent motifs as well as allele-independent supermotifs.
    Geluk A; Van Meijgaarden KE; Drijfhout JW; Ottenhoff TH
    Mol Immunol; 1995 Sep; 32(13):975-81. PubMed ID: 7477003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
    Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
    Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
    Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
    J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
    Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
    Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
    Verreck FA; Fargeas CA; Hämmerling GJ
    Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
    Hitzel C; Koch N
    Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of peptide binding to DR molecules by a leupeptin-induced invariant chain fragment.
    Demotz S; Danieli C; Wallny HJ; Majdic O
    Mol Immunol; 1994 Aug; 31(12):885-93. PubMed ID: 8065372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.